Rx Industry May Need To Inject More Funds Into R&D – GSK Exec

Pharmaceutical manufacturers should consider increasing research & development investments to sustain growth, GlaxoSmithKline R&D Chairman Tachi Yamada declared during a Nov. 30 pipeline update

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet